Moomoo AI 已提取核心信息
Virpax Pharmaceuticals, Inc. (VRPX) has reported a transaction involving Chief Scientific Officer Sheila Mathias. The transaction took place on January 29, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Mathias after the transaction was not provided. This information is typically relevant for investors to assess the confidence of company insiders in the firm's prospects.
Virpax Pharmaceuticals, Inc. (VRPX) has reported a transaction involving Chief Scientific Officer Sheila Mathias. The transaction took place on January 29, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Mathias after the transaction was not provided. This information is typically relevant for investors to assess the confidence of company insiders in the firm's prospects.
Virpax Pharmicals, Inc.（VRPX）报告了一笔涉及首席科学官希拉·马蒂亚斯的交易。该交易于 2024 年 1 月 29 日进行。但是，该公告没有透露交易的股票数量、股票的性质、交易价格或股票的总价值。此外，没有提供交易后马蒂亚斯持有的股票数量。这些信息通常与投资者评估公司内部人士对公司前景的信心有关。
Virpax Pharmicals, Inc.（VRPX）报告了一笔涉及首席科学官希拉·马蒂亚斯的交易。该交易于 2024 年 1 月 29 日进行。但是，该公告没有透露交易的股票数量、股票的性质、交易价格或股票的总价值。此外，没有提供交易后马蒂亚斯持有的股票数量。这些信息通常与投资者评估公司内部人士对公司前景的信心有关。
有用
没用
